308-nm Excimer Light for Eczema: What a 25-Adult Study Found
Bottom line: A small paired-lesion study suggests that clinician-delivered 308-nm excimer light may improve selected, localized atopic dermatitis patches. It does not show that an at-home light device treats eczema, and it does not establish how the treatment compares with standard topical care or full-body phototherapy.
What question did the study ask?
People searching for light treatment for eczema can encounter very different technologies under similar language: narrowband UVB booths, UVA1, blue light, lasers and consumer LEDs. A 2023 preliminary clinical study asked a narrower question: in Korean adults with bilateral, symmetric eczematous lesions, did professionally delivered 308-nm excimer light improve the treated lesion more than the person’s untreated comparison lesion?
The investigators enrolled 25 adults older than 19 years. Two withdrew after the first visit, leaving 23 completers. Each participant served as their own control: one matched lesion received excimer light twice weekly for four weeks while the corresponding lesion was used for comparison. Researchers measured eczema severity, transepidermal water loss and epidermal capacitance.
| Study feature | What was reported | Why it matters |
|---|---|---|
| Population | 25 enrolled; 23 completed | A preliminary sample, not a definitive effectiveness trial |
| Design | Paired, symmetric lesions within each participant | Controls some person-to-person differences, but does not blind participants or compare full treatment plans |
| Schedule | Twice weekly for four weeks | The result belongs to this supervised protocol |
| Results | Greater severity improvement in treated lesions (p<0.001); barrier measures also favored treatment (p<0.01) | The abstract did not provide a patient-centered absolute effect size, so statistical significance is not the same as knowing how noticeable the benefit was |
What an older pilot adds—and what it does not
An earlier pilot enrolled 12 adults and six children with localized atopic dermatitis. All 18 completed six to 12 weekly sessions. Investigators reported complete remission in 12, partial remission in three and no remission in three; 44% maintained the achieved result at 16 weeks. That study had no parallel control group and used a variable number of sessions, so its percentages should not be treated as the expected response for every patient.
Together, the two reports support further study of targeted excimer treatment for localized disease. They do not prove superiority to topical corticosteroids, topical calcineurin inhibitors, other prescription options or narrowband UVB. They also do not establish long-term safety from repeated courses.
Why “targeted light” is different from home LEDs and sunshine
Excimer equipment delivers a specific ultraviolet wavelength to a defined skin area under professional supervision. Dose selection, eye protection, skin type, medication history and prior reactions matter. A household red- or blue-light device is not a substitute. The same caution applies to outdoor exposure: sunlight is variable, can burn skin and is not a calibrated eczema treatment. Read our guide on why sun protection and medical phototherapy are different questions.
The new study also should not be merged with the separate AD-Blue sham-controlled blue-light trial. Those devices, wavelengths, protocols and outcomes were different. Likewise, a small UVA1 hand-eczema trial cannot be used as a substitute for excimer evidence.
Questions to take to a dermatology visit
- Is the diagnosis secure, or could a fungal infection, contact dermatitis or another condition be mimicking eczema?
- Is the affected area localized enough for targeted light, and what conventional treatments have already been tried?
- What wavelength, dose-escalation plan, eye protection and visit schedule would be used?
- How will meaningful improvement be measured, and when should treatment stop if it is not helping?
- How do prior skin cancers, photosensitizing medicines or unusual light reactions change the decision?
Where moisturizer fits
Moisturizer and medical phototherapy answer different questions. A fragrance-free cosmetic moisturizer may support hydration and dry-skin comfort between visits, but it is not the light treatment and does not inherit the trial’s results. Dr. Arsy Moisturizer #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort; it is not an eczema drug and was not tested in either excimer study. People receiving phototherapy should follow their treating clinician’s instructions about what to apply before and after a session.
Sources and evidence limits
- 2023 paired-lesion preliminary study of 308-nm excimer light in 25 adults
- 2008 uncontrolled pilot in 18 adults and children
- Context on UVB phototherapy and conflicting long-term observational evidence
Image note: The hero image is an AI-created editorial illustration using a fictional adult and a nonspecific dermatitis-like patch. It is not a patient photograph, diagnosis, before-and-after comparison or result of Dr. Arsy #003.